NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free ALVR Stock Alerts $0.80 -0.01 (-1.24%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.78▼$0.8150-Day Range$0.71▼$0.8152-Week Range$0.62▼$6.12Volume164,331 shsAverage Volume320,297 shsMarket Capitalization$91.71 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AlloVir alerts: Email Address AlloVir MarketRank™ Stock AnalysisAnalyst RatingReduce1.83 Rating ScoreUpside/Downside2,218.3% Upside$18.50 Price TargetShort InterestBearish5.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$71,175 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.47) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector682nd out of 904 stocksBiological Products, Except Diagnostic Industry113th out of 153 stocks 2.9 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on 1 buy rating, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageAlloVir has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.57% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in AlloVir has recently increased by 1.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for AlloVir this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,175.00 in company stock.Percentage Held by Insiders39.97% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to grow in the coming year, from ($0.47) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About AlloVir Stock (NASDAQ:ALVR)Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.Read More ALVR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALVR Stock News HeadlinesMay 1, 2024 | finance.yahoo.comAlloVir, Inc. (ALVR)March 21, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRMarch 19, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 18, 2024 | investorplace.comALVR Stock Earnings: AlloVir Misses EPS for Q4 2023March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities ...March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVRMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...March 15, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 15, 2024 | prnewswire.comALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 14, 2024 | prnewswire.comClass Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law FirmMarch 14, 2024 | stockhouse.com5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 12, 2024 | prnewswire.comALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVRMarch 12, 2024 | prnewswire.comAlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVRMarch 11, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 9, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 8, 2024 | markets.businessinsider.comALLOVIR INVESTOR ALERT: Kirby McInerney LLP Alerts AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMarch 7, 2024 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVRMarch 6, 2024 | prnewswire.comLost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMarch 5, 2024 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVRMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRFebruary 29, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) InvestorsFebruary 27, 2024 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmFebruary 27, 2024 | prnewswire.comShareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVRFebruary 25, 2024 | prnewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVRFebruary 23, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming DeadlineSee More Headlines Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+2,218.3%Consensus RatingReduce Rating Score (0-4)1.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.73% Return on Assets-78.86% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book0.62Miscellaneous Outstanding Shares114,920,000Free Float68,984,000Market Cap$91.71 million OptionableOptionable Beta0.79 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. David L. Hallal (Age 58)Executive Chairman of the Board Comp: $254.38kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $978.99kMr. Vikas Sinha C.A. (Age 61)CPA, M.B.A., President, CFO & Director Comp: $536.21kMr. Edward Miller J.D. (Age 59)General Counsel & Secretary Comp: $618.39kMr. Brett R. Hagen (Age 51)Chief Accounting Officer Mr. Dana M. Alexander (Age 48)Senior Vice President of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Mr. Ugo Capolino PerlingieriHead & GM of Europe and Middle East OperationsMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsCurisNASDAQ:CRISbluebird bioNASDAQ:BLUEVigil NeuroscienceNASDAQ:VIGLProtalix BioTherapeuticsNYSE:PLXAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 200,464 shares on 4/23/2024Ownership: 0.174%Vikas SinhaSold 1,857 sharesTotal: $1,392.75 ($0.75/share)Edward MillerSold 757 sharesTotal: $567.75 ($0.75/share)Brett R HagenSold 480 sharesTotal: $360.00 ($0.75/share)Vikas SinhaSold 1,521 sharesTotal: $1,140.75 ($0.75/share)View All Insider TransactionsView All Institutional Transactions ALVR Stock Analysis - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ALVR shares. View ALVR analyst ratings or view top-rated stocks. What is AlloVir's stock price target for 2024? 6 Wall Street analysts have issued 12 month price targets for AlloVir's stock. Their ALVR share price targets range from $17.00 to $20.00. On average, they expect the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 2,218.3% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts. How have ALVR shares performed in 2024? AlloVir's stock was trading at $0.6798 at the beginning of the year. Since then, ALVR stock has increased by 17.4% and is now trading at $0.7980. View the best growth stocks for 2024 here. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) posted its quarterly earnings results on Friday, March, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.10. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL). When did AlloVir IPO? AlloVir (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are AlloVir's major shareholders? AlloVir's stock is owned by many different retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALVR) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.